Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haruki Usuda

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Scientific Reports|August 7, 2025
An increase in Fusobacterium is associated with the severity of oral mucositis after radiotherapyAtsushi Ue, Yukihisa Tamaki, Haruki Usuda, et al.
Scientific Reports|August 12, 2021
Juvenile social defeat stress exposure favors in later onset of irritable bowel syndrome-like symptoms in male miceKenjiro Matsumoto, Kana Takata, Daisuke Yamada, et al.
Biological & Pharmaceutical Bulletin|May 3, 2014
Protective effects of fluvoxamine against ischemia/reperfusion injury in isolated, perfused guinea-pig heartsTatsuya Muto, Haruki Usuda, Aya Yamamura, et al.
Bioscience of Microbiota, Food and Health|May 17, 2021
Efficacy of <i>Bifidobacterium bifidum</i> G9-1 in improving quality of life in patients with chronic constipation: a prospective intervention studyAkiko Fuyuki, Takuma Higurashi, Takaomi Kessoku, et al.
Clinical and Translational Gastroenterology|April 30, 2026
Impact of Chronic Constipation and Subtypes on Serum Trimethylamine-N-oxide Levels and Their Reduction with Treatment: Multicenter Observational StudyYo Ishihara, Eikichi Ihara, Hidenori Ohkubo, et al.
Plos One|April 15, 2017
Lubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: A prospective randomized pilot study in healthy volunteersTakayuki Kato, Yasushi Honda, Yusuke Kurita, et al.
BMJ Open|September 10, 2020
Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver diseaseTakaomi Kessoku, Takashi Kobayashi, Anna Ozaki, et al.
Hepatology Communications|October 30, 2023
Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver diseaseMichihiro Iwaki, Takaomi Kessoku, Kosuke Tanaka, et al.
Scientific Reports|December 10, 2021
A prospective interventional trial on the effect of periodontal treatment on Fusobacterium nucleatum abundance in patients with colorectal tumoursTsutomu Yoshihara, Mitomu Kioi, Junichi Baba, et al.
Scientific Reports|August 10, 2022
A cross-sectional study assessing the relationship between non-alcoholic fatty liver disease and periodontal diseaseSatsuki Sato, Yohei Kamata, Takaomi Kessoku, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Scientific Reports|August 7, 2025
An increase in Fusobacterium is associated with the severity of oral mucositis after radiotherapyAtsushi Ue, Yukihisa Tamaki, Haruki Usuda, et al.
Scientific Reports|August 12, 2021
Juvenile social defeat stress exposure favors in later onset of irritable bowel syndrome-like symptoms in male miceKenjiro Matsumoto, Kana Takata, Daisuke Yamada, et al.
Biological & Pharmaceutical Bulletin|May 3, 2014
Protective effects of fluvoxamine against ischemia/reperfusion injury in isolated, perfused guinea-pig heartsTatsuya Muto, Haruki Usuda, Aya Yamamura, et al.
Bioscience of Microbiota, Food and Health|May 17, 2021
Efficacy of <i>Bifidobacterium bifidum</i> G9-1 in improving quality of life in patients with chronic constipation: a prospective intervention studyAkiko Fuyuki, Takuma Higurashi, Takaomi Kessoku, et al.
Clinical and Translational Gastroenterology|April 30, 2026
Impact of Chronic Constipation and Subtypes on Serum Trimethylamine-N-oxide Levels and Their Reduction with Treatment: Multicenter Observational StudyYo Ishihara, Eikichi Ihara, Hidenori Ohkubo, et al.
Plos One|April 15, 2017
Lubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: A prospective randomized pilot study in healthy volunteersTakayuki Kato, Yasushi Honda, Yusuke Kurita, et al.
BMJ Open|September 10, 2020
Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver diseaseTakaomi Kessoku, Takashi Kobayashi, Anna Ozaki, et al.
Hepatology Communications|October 30, 2023
Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver diseaseMichihiro Iwaki, Takaomi Kessoku, Kosuke Tanaka, et al.
Scientific Reports|December 10, 2021
A prospective interventional trial on the effect of periodontal treatment on Fusobacterium nucleatum abundance in patients with colorectal tumoursTsutomu Yoshihara, Mitomu Kioi, Junichi Baba, et al.
Scientific Reports|August 10, 2022
A cross-sectional study assessing the relationship between non-alcoholic fatty liver disease and periodontal diseaseSatsuki Sato, Yohei Kamata, Takaomi Kessoku, et al.
Pageof 4